Logistics · Good distribution practice
How to qualify a freight forwarder for pharmaceutical shipments
A manufacturer should qualify a freight forwarder the way the EU Good Distribution Practice guidelines (2013/C 343/01) treat any outsourced activity: assess its competence, audit it before work begins and whenever the activity changes, and bind it with a written contract. WHO Technical Report Series No. 961, Annex 9, adds a formal service level agreement for temperature control.
Why does a freight forwarder need qualifying at all?
Because the forwarder handles your product during the part of the journey you can see least, and the responsibility stays with you. Chapter 9 of the European Commission Guidelines of 5 November 2013 on Good Distribution Practice of medicinal products for human use (2013/C 343/01), the EU GDP guidelines, says the supplying wholesale distributor is responsible for protecting medicinal products against breakage, adulteration and theft, and for keeping temperature conditions within acceptable limits during transport.1
A point of reading matters here. Neither the EU GDP guidelines nor WHO Technical Report Series No. 961, Annex 9, set out a freight forwarder qualification checklist, and neither names the forwarder as a regulated party. What follows applies their general principles on outsourced activities, carriers and contractors to the forwarder you appoint. That is our reading of those texts, not a quotation of a forwarder rule.
What do the EU GDP rules on outsourced activities require?
A defined, agreed and controlled activity, under a written contract. Section 7.1 of the EU GDP guidelines says any outsourced activity covered by the guide should be correctly defined, agreed and controlled to avoid misunderstandings that could affect the integrity of the product, and that there must be a written contract between the contract giver and the contract acceptor which clearly establishes the duties of each party.1
Chapter 9 connects this directly to transport. Section 9.2 says that where transportation is performed by a third party, the contract in place should encompass the requirements of chapter 7.1 Read together, the forwarder sits in the role of contract acceptor, and you remain responsible for the activities contracted out (section 7.2).
What should a pharmaceutical freight forwarder audit look at?
Whether the forwarder can actually do the work. Section 7.3 of the EU GDP guidelines says the contract acceptor should have adequate premises and equipment, procedures, knowledge and experience, and competent personnel to carry out the work ordered by the contract giver.1 Those headings are a sensible frame for the assessment.
On timing, section 7.2 says an audit of the contract acceptor should be performed before commencement of, and whenever there has been a change to, the outsourced activities. The frequency of audit should be defined based on risk, depending on the nature of the outsourced activities, and audits should be permitted at any time.1
What belongs in a service level agreement for temperature-controlled transport?
Clear responsibility for keeping the load within the product's temperature profile. Section 6.4.1 of WHO Technical Report Series No. 961, Annex 9, Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products (2011), says any carrier contracted to transport such products by air or by sea should operate under a formal service level agreement drawn up between the parties, and that the carrier is to be made responsible for maintaining load temperatures within the transport temperature profile defined for each product.2
For temperature-controlled road vehicles operated by common carriers, the same guidance says temperature control must be qualified, with the details and responsibilities for that process set out in a formal service level agreement. The stated reason is that compliance can then be demonstrated to the contracting organization, the regulatory authorities and other interested parties.2 EU GDP section 9.2 adds that transportation providers should be made aware of the transport conditions that apply to the consignment.1
How do you control subcontracted carriers and transit hubs?
Through the contract and through evidence, not trust. A forwarder often books other carriers, and section 11.3.3 of WHO Technical Report Series No. 961, Annex 9, says every contractor under a service level agreement should provide periodic evidence of compliance with the GSP and/or GDP standards incorporated into that agreement.2 Section 7.3 of the EU GDP guidelines adds that the contract acceptor should refrain from any activity that may adversely affect product quality, and must forward any information that can influence quality to the contract giver as the contract requires.1
Hubs need particular care. Section 9.2 says that where the route includes unloading and reloading or transit storage at a transportation hub, particular attention should be paid to temperature monitoring, cleanliness and the security of any intermediate storage facilities, and that provision should be made to minimise the time spent in temporary storage while awaiting the next stage.1 WHO Annex 9, section 6.3, also asks that transport routes be profiled and qualified.2 For the choice of mode itself, see air or sea freight for temperature-sensitive product, and for what to ask for if something goes wrong in transit, see temperature excursion evidence.
How does this apply to shipments into the Republic of Yemen?
The EU and WHO texts above are an international baseline for any lane, not a statement of what the Republic of Yemen requires of a forwarder. Local specifics are confirmed case by case. For the handover at arrival, see keeping the cold chain intact from the port to the warehouse, and for the wider market picture, entering the Yemen market. The same audit logic applies to the receiving partner, covered in qualifying a distributor.
Frequently asked questions
How should a manufacturer qualify a freight forwarder before shipping pharmaceutical products?
Treat the forwarder as an outsourced activity under the EU Good Distribution Practice guidelines (2013/C 343/01): assess its competence, audit it before work starts and whenever the activity changes, and sign a written contract that sets out each party's duties. For temperature-sensitive product, WHO Technical Report Series No. 961, Annex 9, adds a formal service level agreement.
Do the EU GDP guidelines name the freight forwarder as a regulated party?
No. Chapter 7 of the EU Good Distribution Practice guidelines speaks of a contract giver and a contract acceptor for any outsourced activity, and chapter 9 says a third party transport contract should encompass those requirements. Applying them to a forwarder is a reading of those principles, not a quotation of a forwarder rule.
How often should a freight forwarder be audited?
The EU Good Distribution Practice guidelines say an audit of the contract acceptor should be performed before the outsourced activity starts and whenever it changes, that audit frequency should be defined based on risk depending on the nature of the activity, and that audits should be permitted at any time. They set no fixed interval.
What should a service level agreement for temperature-controlled transport cover?
WHO Technical Report Series No. 961, Annex 9, says a carrier moving temperature-sensitive product by air or sea should work under a formal service level agreement that makes it responsible for keeping load temperatures within each product's defined transport temperature profile, so that compliance can be demonstrated to the contracting organization and regulators.
References
- European Commission, Guidelines of 5 November 2013 on Good Distribution Practice of medicinal products for human use (2013/C 343/01), chapter 7 Outsourced activities, sections 7.1 to 7.3, and chapter 9 Transportation, sections 9.1 and 9.2. Accessed 27 October 2026. health.ec.europa.eu
- World Health Organization, Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products, WHO Technical Report Series No. 961, Annex 9 (2011), sections 6.3, 6.4.1 and 11.3.3. Accessed 27 October 2026. who.int